The decline in Johnson & Johnson’s stock price highlights tensions within the medical device sector. The weakness in medtech could outweigh the strength of the pharmaceutical sector. This dynamic raises questions about pharma’s ability to support overall healthcare stocks.
Source: Read the original article
Disclaimer: this content is for information purposes only and is not financial advice. Cryptocurrencies are highly volatile: you may lose all of your capital. Always do your own research. Legal notice
